Page last updated: 2024-09-05

sb 203580 and formononetin

sb 203580 has been researched along with formononetin in 1 studies

Compound Research Comparison

Studies
(sb 203580)
Trials
(sb 203580)
Recent Studies (post-2010)
(sb 203580)
Studies
(formononetin)
Trials
(formononetin)
Recent Studies (post-2010) (formononetin)
3,48941,13748310314

Protein Interaction Comparison

ProteinTaxonomysb 203580 (IC50)formononetin (IC50)
Neuraminidase Influenza A virus (A/Wilson-Smith/1933(H1N1))3.6225

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Bazer, FW; Lim, W; Park, S; Song, G1

Other Studies

1 other study(ies) available for sb 203580 and formononetin

ArticleYear
The O-methylated isoflavone, formononetin, inhibits human ovarian cancer cell proliferation by sub G0/G1 cell phase arrest through PI3K/AKT and ERK1/2 inactivation.
    Journal of cellular biochemistry, 2018, Volume: 119, Issue:9

    Topics: Analysis of Variance; Antineoplastic Agents; Apoptosis; Butadienes; Cell Line, Tumor; Cell Proliferation; Chromones; Drug Synergism; Enzyme Inhibitors; Female; G1 Phase; Humans; Imidazoles; Isoflavones; MAP Kinase Signaling System; Matrix Metalloproteinases; Membrane Potential, Mitochondrial; Morpholines; Nitriles; Ovarian Neoplasms; p38 Mitogen-Activated Protein Kinases; Phosphatidylinositol 3-Kinases; Phosphorylation; Proto-Oncogene Proteins c-akt; Pyridines; Reactive Oxygen Species; Resting Phase, Cell Cycle; Signal Transduction

2018